Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

What Was Tested

The trial (phase 4) is built around Semaglutide and Dulaglutide.

Participants will: * Take the treatment described according to the Summary of Product Characteristics (SmPC). * Visit the clinic once every 12 weeks for checkups and tests. * Keep a diary of their symptoms to inform the Investigator.

It had two arms (groups): one (experimental) and Standard treatment (active comparator).

The registry classes the interventions as drug.

More on the Plan

Despite current therapies, many patients fail to achieve adequate glycemic control, highlighting the need for more personalized approaches.

Study Design: This is a Phase IV, multicenter, randomized, controlled, two-arm, crossover clinical trial.

Once proven to meet eligibility criteria, patients will be assigned to a treatment arm and will participate in the study for the next 24 weeks.

Safety Objective: To evaluate the safety and tolerability of the glucose control drugs prescribed in each group of patients.

Who Took Part

The registry lists 92 actual participants took part.

It was open to people of any sex aged from 40 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 40-70 years old, included. Body Mass Index (BMI) between 25-40 kg/m². Diagnosis of Type 2 Diabetes (T2D) according to the American Diabetes Association (ADA) criteria. The subject has provided written informed consent prior to any study-specific procedure. Able and willing to comply with requested study visits and procedures.

The full record lists 10 inclusion and 12 exclusion criteria; among the exclusions: treatment with insulin at the time of screening; treatment with more than 3 glucose-lowering drugs at the time of screening; hepatic insufficiency, which contraindicates the use of glucose-lowering drugs.

How the Study Was Run

Design: randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Only one side, usually the participants, was kept unaware of whether Semaglutide was given.

Those kept unaware of assignments: participant.

It started in 2025-05-26 with completion listed for 2026-06-30.

It ran at 3 sites in Spain (3).

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide and Dulaglutide in 92 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page and the Dulaglutide compound page, all human trials.